Exela Pharma Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Exela Pharma Sciences's estimated annual revenue is currently $69.5M per year.
- Exela Pharma Sciences's estimated revenue per employee is $201,000
Employee Data
- Exela Pharma Sciences has 346 Employees.
- Exela Pharma Sciences grew their employee count by 5% last year.
Exela Pharma Sciences's People
Name | Title | Email/Phone |
---|
Exela Pharma Sciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.8M | 29 | 4% | N/A | N/A |
#2 | $3.2M | 16 | 0% | N/A | N/A |
#3 | $83.2M | 414 | 7% | N/A | N/A |
#4 | $31M | 154 | 56% | N/A | N/A |
#5 | $66.6M | 265 | 0% | $35M | N/A |
#6 | $10.9M | 54 | 6% | N/A | N/A |
#7 | $6.8M | 34 | -6% | N/A | N/A |
#8 | $165.7M | 216 | 14% | $250.7M | N/A |
#9 | $26.5M | 132 | -11% | $637.8K | N/A |
#10 | $49.4M | 246 | 6% | N/A | N/A |
What Is Exela Pharma Sciences?
Exela Pharma Sciences, a fast-growing specialty pharmaceutical company, focuses on developing, manufacturing and marketing generic and proprietary injectable and sterile ophthalmic products that keep the healthcare provider and patient in mind. Our goal is to deliver high quality, affordable products that make a difference in people's lives, and also meet the needs of the healthcare providers that treat them. Exela targets the development and manufacturing of generic and proprietary injectable and sterile ophthalmic products with high barriers to market entry, via an Abbreviated New Drug Approval or 505(b)(2) regulatory pathway. We develop products that enhance the patient or provider experience such as easing the burden of administration, providing an improved safety profile, faster drug perparation, or reduce drug waste. In other words, we strive to improve patient outcomes while reducing overall health care costs.
keywords:N/AN/A
Total Funding
346
Number of Employees
$69.5M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Exela Pharma Sciences News
... the U.S. Food and Drug Administration for its cysteine hydrochloride injection, a bioequivalent generic of Exela Pharma Sciences' Elcys.
Prior to 2019, cysteine was sold in the United States as a grandfathered or unapproved product. In 2019, Exela Pharma Sciences received FDA...
Eton's drug is a bioequivalent generic of Exela Pharma Sciences' Elcys, which the FDA approved in 2019. The FDA granted Eton 180 days of...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $147.1M | 410 | 6% | N/A |
#2 | $299.1M | 1187 | 9% | N/A |